ライフサイエンスコーパス: hypolipidemic

1 o those of parent lead structures (i.e., the hypolipidemic 2-hydroxy-2-aryl-(benzo)oxa(or thia)zine a

2 wever, when GLP-1 activity is sustained, the hypolipidemic action of GLP-1 predominates.

3 dation via PERPP, and may be relevant to the hypolipidemic actions of dietary PUFAs, the basal regula

4 tory, and squalene synthase (SQS) inhibitory/hypolipidemic activities are combined in simple molecule

5 exhibited substantial antihyperglycemic and hypolipidemic activities when orally administered in thr

6 digestion resistant maltodextrin exert their hypolipidemic activity by different mechanisms.

7 glycemic efficacy in a db/db mouse model and hypolipidemic activity in hamster and dog models without

8 is likely that this effect accounts for the hypolipidemic activity of these phytosteroids.

9 lower cholesterol which has been found as a hypolipidemic agent in commercial red yeast rice.

10 We investigated the effects of a hypolipidemic agent, nordihydroguaiaretic acid (NDGA), o

11 se have the potential to be a novel class of hypolipidemic agent, which possess combined hypocholeste

12 ses that are highly inducible by fibric acid hypolipidemic agents and other peroxisome proliferators.

13 scular risk independent of changes in use of hypolipidemic agents, smoking, blood pressure, BMI, or l

14 mprove the safety and effectiveness of these hypolipidemic agents.

15 site manners by ritonavir and bezafibrate, a hypolipidemic agonist of the peroxisome proliferator-act

16 nthesis of a trifluoromethylated analog of a hypolipidemic and anti-obesity agent.

17 or-mediated actions pertain to their role in hypolipidemic and antidiabetic therapies and as potentia

18 Hypolipidemic and antihyperlipidemic effect from an aque

19 Evidently the extract possesses pronounced hypolipidemic and antihyperlipidemic effects which are c

20 hese compounds as a new class of dual-acting hypolipidemic and antiobesity agents.

21 Hypolipidemic and antiobesity effects of the newly synth

22 The hypolipidemic and antioxidant actions of thymoquinone (T

23 Gnasxl(m+/p-) mice were hypolipidemic and had increased glucose tolerance and in

24 Gemfibrozil is a widely used hypolipidemic and triglyceride lowering drug.

25 st has focused on various herbs that possess hypolipidemic, antiplatelet, antitumor, or immune-stimul

26 These hypolipidemic apoE2 transgenic mice were cross-bred with

27 , without modifying the diet or initiating a hypolipidemic drug, by the transient induction of Cre ex

28 s the primary target of the fibrate class of hypolipidemic drugs and mediates lipid lowering in part

29 ferators are of exogenous origin and include hypolipidemic drugs and other industrial chemicals, seve

30 how here that specific FAs, eicosanoids, and hypolipidemic drugs are ligands for PPARalpha or PPARdel

31 vated by diverse environmental chemicals and hypolipidemic drugs classified as peroxisome proliferato

32 eptor-alpha (PPARalpha), the target for most hypolipidemic drugs in current clinical use, regulates t

33 unds including fatty acids, eicosanoids, and hypolipidemic drugs such as fibrates and thiazolidinedio

34 uctase inhibitors) are an important group of hypolipidemic drugs that are able to modulate inflammati

35 a nuclear receptor activated by fatty acids, hypolipidemic drugs, and peroxisome proliferators (PPs).

36 activators, such as the fibric acid class of hypolipidemic drugs, and PPAR-gamma agonists, including

37 Since PPARalpha activators, which are hypolipidemic drugs, are being prescribed for a signific

38 (PPARalpha) mediates the effects of several hypolipidemic drugs, endogenous fatty acids, and peroxis

39 Numerous compounds, such as hypolipidemic drugs, herbicides, plasticizers, and analg

40 o monitor the effect of statins, a family of hypolipidemic drugs, on synthetic lipid membranes.

41 Hypolipidemic drugs, such as bezafibrate, known activato

42 of beta-oxidation and a prominent target of hypolipidemic drugs.

43 Experiments in humans indicate a profound hypolipidemic effect of fish oil, especially lowering of

44 ult to uncover the biochemical basis for the hypolipidemic effect of fish oils in humans through use

45 that procyanidin A may impart a key role of hypolipidemic effect seen in peanut skin polyphenols.

46 s was conducted to more precisely define the hypolipidemic effects and safety of psyllium when used a

47 AR gamma also abolished the hypoglycemic and hypolipidemic effects of rosiglitazone, demonstrating th

48 The hypolipidemic effects of the fibrate drugs and the antid

49 hing a plausible mechanism of action for the hypolipidemic effects of these extracts.

50 ry roles in determining the antidiabetic and hypolipidemic effects of thiazolidinediones.

51 G-rich oil is a low calorie fat and exhibits hypolipidemic effects.

52 ceptor alpha (PPARalpha) agonist with strong hypolipidemic effects.

53 is recognized as the molecular target of the hypolipidemic fibrate drugs.

54 a from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratifie

55 n on fat excretion in order to elucidate its hypolipidemic mechanism.

56 all persons who are currently candidates for hypolipidemic medication because they are at high risk f

57 BMI), blood pressure, smoking status, use of hypolipidemic medications, and fasting lipids were deter

58 In contrast to the hypolipidemic mice, mice expressing high levels of apoE2

59 oE2 in the transgenic mice leads to either a hypolipidemic or hyperlipidemic phenotype.

60 Fifth, the CoA thioesters of some hypolipidemic peroxisome proliferators bind with high af

61 dely popular because of its hypoglycemic and hypolipidemic properties but various cases of T. polium-

62 of peanut skin (PE) was investigated for its hypolipidemic properties in rats on Western diet.

63 of chitin, is a dietary fibre known for its hypolipidemic properties, which are mainly attributed to

64 including procyanidins and is shown to have hypolipidemic properties.

65 Results show the hypolipidemic property of FVW-FO and reduced HMG-CoA red

66 Hypolipidemic statin drugs, particularly rosuvastatin (R

67 tablished that PPARs are the targets for the hypolipidemic synthetic compounds known as peroxisome pr

68 ould be confounded by pleiotropic effects of hypolipidemic treatment.